TY - JOUR
T1 - Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery
AU - Muntané-Carol, Guillem
AU - Taramasso, Maurizio
AU - Miura, Mizuki
AU - Gavazzoni, Mara
AU - Pozzoli, Alberto
AU - Alessandrini, Hannes
AU - Latib, Azeem
AU - Attinger-Toller, Adrian
AU - Biasco, Luigi
AU - Braun, Daniel
AU - Brochet, Eric
AU - Connelly, Kim A.
AU - Sievert, Horst
AU - Denti, Paolo
AU - Lubos, Edith
AU - Ludwig, Sebastian
AU - Kalbacher, Daniel
AU - Estevez-Loureiro, Rodrigo
AU - Fam, Neil
AU - Frerker, Christian
AU - Ho, Edwin
AU - Juliard, Jean Michel
AU - Kaple, Ryan
AU - Kodali, Susheel
AU - Kreidel, Felix
AU - Harr, Claudia
AU - Lauten, Alexander
AU - Lurz, Julia
AU - Kresoja, Karl Patrik
AU - Monivas, Vanessa
AU - Mehr, Michael
AU - Nazif, Tamim
AU - Nickening, Georg
AU - Pedrazzini, Giovanni
AU - Philippon, François
AU - Praz, Fabien
AU - Puri, Rishi
AU - Schäfer, Ulrich
AU - Schofer, Joachim
AU - Tang, Gilbert H.L.
AU - Khattab, Ahmed A.
AU - Andreas, Martin
AU - Russo, Marco
AU - Thiele, Holger
AU - Unterhuber, Matthias
AU - Himbert, Dominique
AU - Urena, Marina
AU - von Bardeleben, Ralph Stephan
AU - Webb, John G.
AU - Weber, Marcel
AU - Winkel, Mirjam
AU - Zuber, Michel
AU - Hausleiter, Jörg
AU - Lurz, Philipp
AU - Maisano, Francesco
AU - Leon, Martin B.
AU - Hahn, Rebecca T.
AU - Rodés-Cabau, Josep
N1 - Funding Information:
Dr Taramasso has served as a consultant for Abbott Vascular, Boston Scientific, 4Tech, and CoreMedic and received speaker honoraria from Edwards Lifesciences. Dr Gavazzoni has served as a consultant for Biotronik. Dr Latib has served on the advisory board for Medtronic and Abbott Vascular, on the Speakers Bureau for Abbott Vascular, on the scientific advisory board for Millipede, and as a consultant for 4Tech, Mitralign, and Millipede. Dr Braun has received speaker honoraria and travel support from Abbott Vascular. Dr Brochet has received speaker fees from Abbott Vascular. Dr Connelly has received honoraria from Abbott Industries. Dr Sievert has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Comed, Contego, CVRx, Edwards, Endologix, Hemoteq, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, PFM Medical, ReCor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical. Dr Denti has served as a consultant for Abbott Vascular, 4Tech, Neovasc, and InnovHeart and received honoraria from Abbott and Edwards. Dr Ludwig has received travel compensation from Edwards Lifesciences. Dr Andreas as served as proctor/consultant for Edwards/Abbott and advisor for Medtronic. Dr Kalbacher has received travel compensation and lecture fees from Abbott and proctor fees and travel compensation from Edwards. Dr Kodali has served on the scientific advisory board for Microinterventional Devices, Dura Biotech, Thubrikar Aortic Valve, and Supira; as a consultant for Meril Lifesciences, Admedus, Medtronic, and Boston Scientific; and on the steering committee for Edwards Lifesciences and Abbott Vascular; has received honoraria from Meril Lifesciences, Admedus, Abbott Vascular, and Dura Biotech; and owns equity in Dura Biotech, Thubrikar Aortic Valve, and Supira. Dr Kreidel has received speaker honoraria and consulting fees from Abbott and Edwards Lifesciences. Dr Lauten has received research support from Abbott and Edwards Lifesciences; and has been a consultant for Abbott, Edwards Lifesciences, and TricValve. Dr Lurz has received speaker fees from Abbott. Dr Nazif has served as a consultant for and received consulting honoraria from Edwards Lifesciences, Boston Scientific, Medtronic, and Biotrace Medical. Dr Praz has been a consultant to Edwards Lifesciences. Dr Schäfer has received lecture fees, study honoraria, travel expenses from and has been served on an advisory board for Abbott. Dr Tang has served as a consultant, advisory board member, and faculty trainer for Abbott Structural Heart. Dr Himbert has served as a proctor for Edwards Lifesciences and Abbott. Dr von Bardeleben has served as an unpaid advisory board member for Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Philips Healthcare and speaker for Abbott Structural, Bioventrix, Cardiac Dimensions, Edwards Lifesciences, and Philips Healthcare. Dr Webb has received research support from Edwards Lifesciences and served as a consultant for Abbott Vascular, Edwards Lifesciences, and St. Jude Medical. Dr Zuber has served as a consultant for Abbott Vascular, Edwards Lifesciences, Cardiovalve, Vortex, CoreMedics, and Cardiovalve and has received speaker fees from Pfizer and Canon. Dr Hausleiter has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. Dr Maisano has served as a consultant for and received consulting fees and honoraria from Abbott Vascular, Edwards Lifesciences, Cardiovalve, SwissVortex, Perifect, Xeltis, Transseptal Solutions, Magenta, Valtech, and Medtronic; is cofounder of 4Tech; has received research grant support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, New Valve Technology, and Terumo; has received royalties and owns intellectual property rights from Edwards Lifesciences (functional mitral regurgitation surgical annuloplasty); and is a shareholder in Cardiovalve, Swiss Vortex, Magenta, Transseptal Solutions, Occlufit, 4Tech, and Perifect. Dr Leon has served as a nonpaid member of the scientific advisory board for Edwards Lifesciences and has been a consultant to Abbott Vascular and Boston Scientific. Dr Hahn has served as a consultant for Abbott Vascular, Abbott Structural, NaviGate, Philips Healthcare, Medtronic, Edwards Lifesciences, and GE Healthcare; is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-supported trials, for which she receives no direct industry compensation; has received speaker fees from Boston Scientific and Baylis Medical; and has received nonfinancial support from 3mensio. Dr Rodés-Cabau has received institutional research grants from Edwards Lifesciences. All other authors have no conflicts of interest to disclose.
Funding Information:
Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions. Dr Muntané-Carol was supported by a grant from the Fundación Alfonso Martín Escudero (Madrid, Spain).
Publisher Copyright:
© 2021 Canadian Cardiovascular Society
PY - 2021/7
Y1 - 2021/7
N2 - Background: Scarce data exist on patients with previous left valve surgery (PLVS) undergoing transcatheter tricuspid valve intervention (TTVI). This study sought to investigate the procedural and early outcomes in patients with PLVS undergoing TTVI. Methods: This was a subanalysis of the multicenter TriValve registry including 462 patients, 82 (18%) with PLVS. Data were analyzed according to the presence of PLVS in the overall cohort and in a propensity score–matched population including 51 and 115 patients with and without PLVS, respectively. Results: Patients with PLVS were younger (72 ± 10 vs 78 ± 9 years; p < 0.01) and more frequently female (67.1% vs 53.2%; P = 0.02). Similar rates of procedural success (PLVS 80.5%; no-PLVS 82.1%; P = 0.73), and 30-day mortality (PLVS 2.4%, no-PLVS 3.4%; P = 0.99) were observed. After matching, there were no significant differences in both all-cause rehospitalisation (PLVS 21.1%, no-PLVS 26.5%; P = 0.60) and all-cause mortality (PLVS 9.8%, no-PLVS 6.7%; P = 0.58). At last follow-up (median 6 [interquartile range 1-12] months after the procedure), most patients (81.8%) in the PLVS group were in NYHA functional class I-II (P = 0.12 vs no-PLVS group), and TR grade was ≤ 2 in 82.6% of patients (P = 0.096 vs no-PVLS group). A poorer right ventricular function and previous heart failure hospitalization determined increased risks of procedural failure and poorer outcomes at follow-up, respectively. Conclusions: In patients with PLVS, TTVI was associated with high rates of procedural success and low early mortality. However, about one-third of patients required rehospitalisation or died at midterm follow-up. These results would support TTVI as a reasonable alternative to redo surgery in patients with PLVS and suggest the importance of earlier treatment to improve clinical outcomes.
AB - Background: Scarce data exist on patients with previous left valve surgery (PLVS) undergoing transcatheter tricuspid valve intervention (TTVI). This study sought to investigate the procedural and early outcomes in patients with PLVS undergoing TTVI. Methods: This was a subanalysis of the multicenter TriValve registry including 462 patients, 82 (18%) with PLVS. Data were analyzed according to the presence of PLVS in the overall cohort and in a propensity score–matched population including 51 and 115 patients with and without PLVS, respectively. Results: Patients with PLVS were younger (72 ± 10 vs 78 ± 9 years; p < 0.01) and more frequently female (67.1% vs 53.2%; P = 0.02). Similar rates of procedural success (PLVS 80.5%; no-PLVS 82.1%; P = 0.73), and 30-day mortality (PLVS 2.4%, no-PLVS 3.4%; P = 0.99) were observed. After matching, there were no significant differences in both all-cause rehospitalisation (PLVS 21.1%, no-PLVS 26.5%; P = 0.60) and all-cause mortality (PLVS 9.8%, no-PLVS 6.7%; P = 0.58). At last follow-up (median 6 [interquartile range 1-12] months after the procedure), most patients (81.8%) in the PLVS group were in NYHA functional class I-II (P = 0.12 vs no-PLVS group), and TR grade was ≤ 2 in 82.6% of patients (P = 0.096 vs no-PVLS group). A poorer right ventricular function and previous heart failure hospitalization determined increased risks of procedural failure and poorer outcomes at follow-up, respectively. Conclusions: In patients with PLVS, TTVI was associated with high rates of procedural success and low early mortality. However, about one-third of patients required rehospitalisation or died at midterm follow-up. These results would support TTVI as a reasonable alternative to redo surgery in patients with PLVS and suggest the importance of earlier treatment to improve clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85108283303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108283303&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2021.02.010
DO - 10.1016/j.cjca.2021.02.010
M3 - Article
C2 - 33617978
AN - SCOPUS:85108283303
SN - 0828-282X
VL - 37
SP - 1094
EP - 1102
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 7
ER -